{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:20:17Z","timestamp":1787926817494,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metabolic reprogramming disrupts energy homeostasis and promotes tumor cell proliferation. In the present study, high expression of adipose triglyceride lipase (ATGL) in patients with acute myeloid leukemia (AML) predicted a poor clinical prognosis. Furthermore, the aberrant upregulation of ATGL was confirmed to promote the malignant progression of AML through gene ablation, overexpression, and pharmacological inhibition of ATGL, particularly in FLT3-ITD-mutated AML. RNA sequencing, lipid peroxidation, cellular iron, and ROS assays were performed to confirm the association of ATGL with ferroptosis. Mechanistically, ATGL is positively correlated with stearoyl-CoA decarboxylase 1 (SCD1) and promotes the malignant progression of AML by inhibiting ferroptosis through the CEBP\u03b1\/SCD1 axis. We established gilteritinib-resistant MOLM-13 and MV4-11 cell lines and collected cells from patients with\n                    <jats:italic>FLT3<\/jats:italic>\n                    -ITD mutations to confirm that ATGL inhibitors increased the efficacy of gilteritinib. Consequently, we constructed an AML xenograft model using cells derived from patients with\n                    <jats:italic>FLT3<\/jats:italic>\n                    -ITD-mutated AML to confirm the efficacy of combining ATGL inhibitors with gilteritinib in vivo. This study provides novel therapeutic targets and monitoring indicators for AML, along with new treatment strategies for patients with\n                    <jats:italic>FLT3<\/jats:italic>\n                    -ITD-mutated AML and those with relapsed\/refractory\n                    <jats:italic>FLT3<\/jats:italic>\n                    -ITD-mutated AML.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08388-0","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:04:00Z","timestamp":1767942240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ATGL suppresses ferroptosis in acute myeloid leukemia cells by modulating the CEBP\u03b1\/SCD1 axis and induces gilteritinib resistance"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-292X","authenticated-orcid":false,"given":"Shiyi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-2832","authenticated-orcid":false,"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-4087","authenticated-orcid":false,"given":"Shifeng","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"8388_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14:49.","journal-title":"J Hematol Oncol"},{"key":"8388_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"8388_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neo.2014.06.002","volume":"16","author":"HW Kao","year":"2014","unstructured":"Kao HW, Liang DC, Wu JH, Kuo MC, Wang PN, Yang CP, et al. Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia. Neoplasia. 2014;16:481\u20138.","journal-title":"Neoplasia"},{"key":"8388_CR4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9:1050\u201363.","journal-title":"Cancer Discov"},{"key":"8388_CR5","doi-asserted-by":"publisher","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.12.006","volume":"29","author":"AE Perl","year":"2023","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Outcomes in patients with FLT3-mutated relapsed\/ refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transplant Cell Ther. 2023;29:265.e1\u2013e10.","journal-title":"Transplant Cell Ther"},{"key":"8388_CR6","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","volume":"187","author":"C Swanton","year":"2024","unstructured":"Swanton C, Bernard E, Abbosh C, Andr\u00e9 F, Auwerx J, Balmain A, et al. Embracing cancer complexity: hallmarks of systemic disease. Cell. 2024;187:1589\u2013616.","journal-title":"Cell"},{"key":"8388_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355\u201377.","journal-title":"Cell Metab"},{"key":"8388_CR8","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1038\/s41375-025-02645-z","volume":"39","author":"V Dembitz","year":"2025","unstructured":"Dembitz V, James SC, Gallipoli P. Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities. Leukemia. 2025;39:1814\u201323.","journal-title":"Leukemia"},{"key":"8388_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","volume":"19","author":"H Ye","year":"2016","unstructured":"Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19:23\u201337.","journal-title":"Cell Stem Cell"},{"key":"8388_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2023.11.017","volume":"36","author":"RJ Wedan","year":"2024","unstructured":"Wedan RJ, Longenecker JZ, Nowinski SM. Mitochondrial fatty acid synthesis is an emergent central regulator of mammalian oxidative metabolism. Cell Metab. 2024;36:36\u201347.","journal-title":"Cell Metab"},{"key":"8388_CR11","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/2159-8290.CD-22-0411","volume":"13","author":"M Sabatier","year":"2023","unstructured":"Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, et al. C\/EBP\u03b1 confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia. Cancer Discov. 2023;13:1720\u201347.","journal-title":"Cancer Discov"},{"key":"8388_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.tem.2017.10.003","volume":"28","author":"AM ALJohani","year":"2017","unstructured":"ALJohani AM, Syed DN, Ntambi JM. Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism. Trends Endocrinol Metab. 2017;28:831\u201342.","journal-title":"Trends Endocrinol Metab"},{"key":"8388_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102006","volume":"43","author":"G Luis","year":"2021","unstructured":"Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E, et al. Tumor resistance to ferroptosis driven by stearoyl-CoA desaturase-1 (SCD1) in cancer cells and fatty acid biding protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021;43:102006.","journal-title":"Redox Biol"},{"key":"8388_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jare.2024.09.027","volume":"74","author":"G Huang","year":"2025","unstructured":"Huang G, Cai Y, Ren M, Zhang X, Fu Y, Cheng R, et al. Salidroside sensitizes triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. J Adv Res. 2025;74:589\u2013607.","journal-title":"J Adv Res"},{"key":"8388_CR15","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.7150\/thno.70194","volume":"12","author":"Y Xuan","year":"2022","unstructured":"Xuan Y, Wang H, Yung MM, Chen F, Chan WS, Chan YS, et al. SCD1\/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells. Theranostics. 2022;12:3534\u201352.","journal-title":"Theranostics"},{"key":"8388_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153\u201361.","journal-title":"Cell Metab"},{"key":"8388_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763\u201377.","journal-title":"Nat Rev Cancer"},{"key":"8388_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732\u201349.","journal-title":"Nat Rev Cancer"},{"key":"8388_CR19","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1182\/blood.V87.8.3395.bloodjournal8783395","volume":"87","author":"JW Taub","year":"1996","unstructured":"Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood. 1996;87:3395\u2013403.","journal-title":"Blood"},{"key":"8388_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0145-2126(96)00132-4","volume":"21","author":"H Quentmeier","year":"1997","unstructured":"Quentmeier H, Zaborski M, Drexler HG. The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines. Leuk Res. 1997;21:343\u201350.","journal-title":"Leuk Res"},{"key":"8388_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou\u2013Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"8388_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621\u201381.","journal-title":"Pharmacol Rev"},{"key":"8388_CR23","doi-asserted-by":"crossref","unstructured":"Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218:1\u201317.","DOI":"10.1084\/jem.20201606"},{"key":"8388_CR24","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56:1363\u201393.","journal-title":"Dev Cell"},{"key":"8388_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cmet.2020.09.001","volume":"32","author":"D Forte","year":"2020","unstructured":"Forte D, Garc\u00eda-Fern\u00e1ndez M, S\u00e1nchez-Aguilera A, Stavropoulou V, Fielding C, Mart\u00edn-P\u00e9rez D, et al. Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy. Cell Metab. 2020;32:829\u201343.e9.","journal-title":"Cell Metab"},{"key":"8388_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03156-8","volume":"11","author":"A Polak","year":"2020","unstructured":"Polak A, Bialopiotrowicz E, Krzymieniewska B, Wozniak J, Stojak M, Cybulska M, et al. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. Cell Death Dis. 2020;11:956.","journal-title":"Cell Death Dis"},{"key":"8388_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931\u201347.","journal-title":"Nat Rev Drug Discov"},{"key":"8388_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ccr.2006.08.009","volume":"10","author":"D Trachootham","year":"2006","unstructured":"Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 2006;10:241\u201352.","journal-title":"Cancer Cell"},{"key":"8388_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00373-4","volume":"10","author":"R Iftikhar","year":"2021","unstructured":"Iftikhar R, Penrose HM, King AN, Samudre JS, Collins ME, Hartono AB, et al. Elevated ATGL in colon cancer cells and cancer stem cells promotes metabolic and tumorigenic reprogramming reinforced by obesity. Oncogenesis. 2021;10:82.","journal-title":"Oncogenesis"},{"key":"8388_CR30","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.cmet.2022.11.003","volume":"34","author":"Z Gong","year":"2022","unstructured":"Gong Z, Li Q, Shi J, Liu ET, Shultz LD, Ren G. Lipid-laden lung mesenchymal cells foster breast cancer metastasis via metabolic reprogramming of tumor cells and natural killer cells. Cell Metab. 2022;34:1960\u201376.","journal-title":"Cell Metab"},{"key":"8388_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1158\/0008-5472.CAN-23-0555","volume":"84","author":"D Awad","year":"2024","unstructured":"Awad D, Cao PHA, Pulliam TL, Spradlin M, Subramani E, Tellman TV, et al. Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity. Cancer Res. 2024;84:703\u201324.","journal-title":"Cancer Res"},{"key":"8388_CR32","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716\u201335.","journal-title":"Cancer Discov"},{"key":"8388_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.693","volume":"5","author":"S Wang","year":"2024","unstructured":"Wang S, Guo S, Guo J, Du Q, Wu C, Wu Y, et al. Cell death pathways: molecular mechanisms and therapeutic targets for cancer. MedComm (2020). 2024;5:e693.","journal-title":"MedComm (2020)"},{"key":"8388_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38581-8","volume":"14","author":"TL Wong","year":"2023","unstructured":"Wong TL, Loh JJ, Lu S, Yan HHN, Siu HC, Xi R, et al. ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer. Nat Commun. 2023;14:2861.","journal-title":"Nat Commun"},{"key":"8388_CR35","doi-asserted-by":"publisher","first-page":"e2006203","DOI":"10.1371\/journal.pbio.2006203","volume":"16","author":"H Feng","year":"2018","unstructured":"Feng H, Stockwell BR. Unsolved mysteries: How does lipid peroxidation cause ferroptosis?. PLoS Biol. 2018;16:e2006203.","journal-title":"PLoS Biol"},{"key":"8388_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369\u201379.","journal-title":"Cell Death Differ"},{"key":"8388_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","volume":"5","author":"D Li","year":"2020","unstructured":"Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Target Ther. 2020;5:108.","journal-title":"Signal Transduct Target Ther"},{"key":"8388_CR38","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/0008-5472.CAN-19-0515","volume":"79","author":"M Hosseini","year":"2019","unstructured":"Hosseini M, Rezvani HR, Aroua N, Bosc C, Farge T, Saland E, et al. Targeting myeloperoxidase disrupts mitochondrial redox balance and overcomes cytarabine resistance in human acute myeloid leukemia. Cancer Res. 2019;79:5191\u2013203.","journal-title":"Cancer Res"},{"key":"8388_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1172\/JCI38942","volume":"120","author":"I Samudio","year":"2010","unstructured":"Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Investig. 2010;120:142\u201356.","journal-title":"J Clin Investig"},{"key":"8388_CR40","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"Y Cao","year":"2019","unstructured":"Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Investig. 2019;129:3006\u201317.","journal-title":"J Clin Investig"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08388-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08388-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08388-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:32:54Z","timestamp":1770298374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08388-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8388"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08388-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}